253 completed, 33 terminated, 21 recruiting, 19 active not recruiting. 202 Phase 1, 72 Phase 2, 60 Phase 3, 13 Phase 4, 3 Not applicable.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 1 | 202 | Completed 153, Terminated 20, Recruiting 12, Active not recruiting 7, Unknown 6, Withdrawn 3, Not yet recruiting 1 |
| Phase 2 | 72 | Completed 43, Terminated 7, Recruiting 6, Unknown 6, Active not recruiting 5, Withdrawn 4, Not yet recruiting 1 |
| Phase 3 | 60 | Completed 45, Active not recruiting 6, Recruiting 4, Terminated 2, Withdrawn 2, Suspended 1 |
| Phase 4 | 13 | Completed 10, Recruiting 1, Terminated 1, Withdrawn 1 |
| Not applicable | 3 | Completed 2, Terminated 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Parexel: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate Ofirnoflast in Adults With Very Low- to Intermediate-risk Myelodysplastic Syndromes Requiring Red Blood Cell Transfusions
Ofirnoflast - Myelodysplastic Syndromes, Anemia | Phase 2 | Not yet recruiting | 70 | 2026-11-01 | 2026-10-02 |
Study to Characterise Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Anifrolumab Administered Subcutaneously (SC) or Intravenously (IV)
Anifrolumab: SC formulation via AI, Anifrolumab: IV formulation, Anifrolumab: SC formulation via aPFS - Systemic Lupus Erythematosus | Phase 1 | Not yet recruiting | 92 | 2026-10-30 | 2026-07-07 |
A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.
NHS7108, Zenpep® - Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF) | Phase 2 | Recruiting | 66 | 2026-10-01 | 2026-10-01 |
A Study to Investigate the Safety and Pharmacokinetics of Single- and Multiple-ascending Doses of AZD4916 in Healthy Volunteers
AZD4916, Placebo - Healthy Participants | Phase 1 | Recruiting | 160 | 2026-07-23 | 2026-09-28 |
A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults
AZD7760, Placebo - Staphylococcus Aureus Bloodstream Infection | Phase 1 | Active not recruiting | 18 | 2026-06-29 | 2026-10-06 |
A Study to Evaluate the Effect of Carbamazepine or Itraconazole on Radiprodil in Healthy Adult Participants
Radiprodil, Carbamazepine, Itraconazole (200 mg) - Healthy Adult Participants | Phase 1 | Active not recruiting | 36 | 2026-06-08 | 2026-10-21 |
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
Surovatamig - Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV | Phase 3 | Recruiting | 420 | 2026-05-05 | 2026-10-06 |
A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants
Elecoglipron, Atorvastatin, Rosuvastatin - Healthy Participants | Phase 1 | Active not recruiting | 48 | 2026-04-16 | 2026-08-28 |
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
AZD1043, Placebo - Healthy Participants, Obesity | Phase 1 | Recruiting | 104 | 2026-03-30 | 2026-10-13 |
A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy Participants
Dextromethorphan, Capivasertib - Healthy Participants | Phase 1 | Completed | 42 | 2026-03-19 | 2026-07-27 |
A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults
Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1, Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2 - Healthy Participants | Phase 1 | Completed | 44 | 2026-03-16 | 2026-06-17 |
A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants
AZD5004, Mitiglinide, Pioglitazone - Healthy Participants | Phase 1 | Completed | 32 | 2026-03-13 | 2026-07-13 |
A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years
AZD5004 - Healthy Participants | Phase 1 | Completed | 65 | 2026-03-05 | 2026-06-10 |
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics With AZD0780 Following Repeated Dose Administration in Healthy Adults With Elevated LDL-C Levels
AZD0780, Placebo - Healthy Participants | Phase 1 | Completed | 40 | 2026-02-24 | 2026-07-07 |
A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
CKD-706, US-Dupixent, EU-Dupixent - Atopic Dermatitis | Phase 1 | Recruiting | 519 | 2026-02-09 | 2026-01-23 |
A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants
Andexanet alfa, Rivaroxaban, Apixaban - Healthy Participants | Phase 1 | Completed | 191 | 2026-01-19 | 2026-07-09 |
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
Capivasertib - Moderate Hepatic Impairment | Phase 1 | Recruiting | 20 | 2026-01-06 | 2026-09-09 |
A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy
PLENVU®, Sodium picosulfate - Bowel Cleansing Prior to Clinical Procedures | Phase 3 | Recruiting | 212 | 2025-12-29 | 2026-10-07 |
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy Participants
AZD3974, Placebo - Healthy Participants | Phase 1 | Recruiting | 176 | 2025-12-10 | 2026-10-13 |
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
IV Rilvegostomig, Recombinant Human Hyaluronidase (rHu), SC Rilvegostomig - Advanced Solid Tumors | Phase 1 | Recruiting | 40 | 2025-11-25 | 2026-10-05 |
Showing 20 of 352. Sign in to see all of them.
Conditions studied
Asthma (27) · Pulmonary Disease, Chronic Obstructive (22) · Diabetes Mellitus, Type 2 (15) · Carcinoma, Non-Small-Cell Lung (14) · Renal Insufficiency, Chronic (12) · Arthritis, Rheumatoid (10) · Obesity (10) · Dyslipidemias (8) · Heart Failure (8) · Neoplasms (8) · Prostatic Neoplasms (7) · Axial Spondyloarthritis (5) · Cardiovascular Diseases (5) · Crohn Disease (5) · Lung Neoplasms (5)
Interventions
Itraconazole (9) · Certolizumab Pegol (7) · Rosuvastatin Calcium (7) · capivasertib (7) · 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (6) · Moxifloxacin (6) · dapagliflozin (6) · AZD4831 (5) · AZD5718 (5) · durvalumab (5) · osimertinib (5) · AZD-8871 (4) · Allopurinol (4) · Budesonide (4) · Midazolam (4)
Countries
United States (194) · United Kingdom (93) · Germany (84) · Spain (49) · Poland (45) · Italy (39) · Canada (37) · France (30) · South Korea (30) · Hungary (27) · Japan (27) · Australia (26) · Taiwan (26) · Bulgaria (24) · China (24)
Top investigators
David Han, MD (5) · Ronald Goldwater, MD (4) · Christoph Gasche, Professor (2) · David Han, M.D (2) · Esther Yoon, MD (2) · Muna Albayaty, MBChB, MSc, MFPM (2) · Muna Albayaty, MD (2) · Pablo Forte Soto, MD, MSc, PhD (2)
Results publications
PMID 28285236, PMID 30968588, PMID 32907575, PMID 35544084, PMID 39798707, PMID 41677208, PMID 19834012, PMID 21852153, PMID 22500920, PMID 23078888, PMID 23169518, PMID 23907766, PMID 24586912, PMID 25453582, PMID 25700806, PMID 25701171, PMID 26016741, PMID 26045340, PMID 26047892, PMID 26160357, PMID 26547100, PMID 26949137, PMID 26980471, PMID 27139036, PMID 27207107, PMID 27297209, PMID 27579634, PMID 27863807, PMID 28158463, PMID 28814432, PMID 28905294, PMID 29030361, PMID 29093180, PMID 29151359, PMID 29158123, PMID 29275332, PMID 29869298, PMID 29902133, PMID 30130439, PMID 30181096, PMID 30239252, PMID 30508196, PMID 30566758, PMID 30659024, PMID 30723727, PMID 30957581, PMID 31140114, PMID 31266654, PMID 31332045, PMID 31439584
NIH funding
2017 (7), 2016 (6), 2025 (6), 2009 (5), 2019 (5), 2014 (4), 2015 (4), 2008 (3), 2018 (3), 2023 (3), UM1AI104681 (1)